How self-care led to Ozempic's success

Some Ozempic users lose their desire to eat

This essay follows a writer whose Ozempic journey involves a dramatic loss of appetite, leading them to stop compulsive snacking and even lose some of the joy of eating. As a result, he becomes fixated on watching food videos and eventually tries to "beat" an all-you-can-eat steak buffet. The experience leaves him feeling disappointed and lacking in desire.

Research suggests Ozempic has benefits beyond weight loss

Semaglutide, the key ingredient in Ozempic, is proving to be more than just a diabetes and weight loss drug. Research suggests it may also help prevent strokes, improve heart health, and slow Alzheimer’s.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

The popularity of new weight loss drugs has led to a diabetes treatment shortage

The FDA approved Ozempic to help patients with diabetes, but the popularity of semaglutide as a weight loss drug led doctors to prescribe Ozempic to nondiabetic patients who needed to lose weight. Ozempic became so popular that manufacturers could not keep pace with demand, posing risks for Ozempic-users with diabetes.

From Ozempic to Wegovy, see the $58B weight loss drug market visualized in one chart.

Can you microdose GLP-1 agonists like Ozempic?

GLP-1 agonists like Ozempic can help with weight loss, diabetes, and anti-inflammation. For some users, normal doses are too much. So, they've started "microdosing"—taking a smaller amount than the lowest increment of the drug available. While not yet backed by clinical trials, some doctors observed positive effects for certain people.

GLP-1 drugs mimic a natural hormone that triggers appetite-suppressing effects

Ozempic, one of the brand names for the drug semaglutide, was originally developed in 2012, to help treat Type 2 diabetes. Among other effects, the drug mimics a naturally produced hormone known as GLP-1, which is released while eating to let our bodies know we are full.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

In 2025, Weight Watchers filed for Chapter 11 bankruptcy after reporting revenue and profit losses for multiple consecutive years, with its stock price losing about 99% of its value between 2018 and 2025.

How weight loss drugs could reduce obesity costs

A detailed analysis from finance giant ING finds semaglutide and other weight loss drugs could significantly drive down global costs stemming from heart disease and other health problems associated with obesity. The benefits will vary, depending on each country’s demographics and drug and healthcare costs.

When people stopped using GLP-1, they regained two-thirds of the weight back.

Weight Watchers began offering access to GLP-1 weight-loss medications in 2023 after losing more than 1.5 million members over the previous two years.

GLP-1s are linked to reduced worker illness and cost savings—a 2026 economic analysis finds the weight-loss drugs are tied to a 17% drop in worker sick leave days.

Activity trackers promise to improve health by forcing us to examine the facts

Explore how modern fitness culture, rooted in capitalist ideals of productivity and control, shapes our perception of health and self-worth. The author blends cultural criticism with personal insight to examine the contradictions of the wellness industry, the rise of wearable tech, and what it means to "optimize" a body.

Talk show host Oprah Winfrey spent about $43M in 2015 to buy a 10% stake in Weight Watchers and join its board of directors, going on to lose 40lbs using the program.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

Insurance coverage for GLP-1s remains uneven, but Medicare began covering it in some instances in July 2026.

At-home genetic testing results commonly led users to healthier lifestyles

Italian research that aimed to investigate what people do longer-term after receiving direct-to-consumer genetic test results indicated that whether the results were positive or negative, people tended to adopt a healthier diet after receiving the results, and they'd still maintained it a year after receiving their results. Some users also reported an overall reduction in stress over their health concerns. (Some users may encounter a paywall.)

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

Ozempic parent company Novo Nordisk operates under a 'foundation ownership model'—meaning that a foundation holds the majority of the company's voting power, while most of its equity is owned by public investors.

Self-care can't fix burnout on its own

Steps such as exercise, breathing, mindful eating, and spending time with friends, can help alleviate the fight-or-flight mode response of the body to alleviate stress, but they don't fix the stressors causing the burnout. To address those, workplaces may need to consider how to better manage workloads and duties.

Medicare in early 2026 did not pay for GLP-1 for obesity treatment, and coverage under Medicaid varied widely by state.

Not everyone who is a candidate for GLP-1 is choosing to use the drug

One person writes about why, although she's a good fit for the medication on paper, she's decided not to take GLP-1 due to concerns about mental health and other side effects, among other reasons.

Tirzepatide: A GLP-1 drug that also acts on separate receptors to promote weight loss

Tirzepatide, like semaglutide, is a GLP-1 drug used in diabetes treatment and for weight loss. Unlike semaglutide, it also acts on glucose-dependent insulinotropic polypeptide receptors, proving a second route to reducing appetite as a means to treat diabetes and promote weight loss.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

Precision medicine, offering the right treatment at the right time for individuals, integrates genomics, data analytics, and AI to predict risks, personalize treatments, and improve patient outcomes.

Easy resets for stress reduction

Individual solutions for burnout, often called “self-care,” can be helpful for managing stress. Harvard researcher Aditi Nerurkar’s 2024 book The Five Resets details a road map for burnout recovery. In this interview she suggests, among other tactics, gaining focus on what matters the most in one’s life, taking breaks from both work and the internet, and making time for practices that strengthen the mind-body connection.

Why we should care about renaming the hormonal disorder PCOS to PMOS

The new name, polyendocrine metabolic ovarian syndrome, nods to the hormonal disruptions that cause this condition, which affects roughly one in eight women. People with PMOS may have symptoms including irregular periods, trouble conceiving, weight gain, acne, undesired hair growth, and more. The earlier name, polycystic ovary syndrome, was a misnomer because women with the condition don't have cysts in their ovaries. Rather, they have masses that are actually immature follicles. World health experts think the condition often goes undiagnosed.

Compounding pharmacies make custom drug formulations during drug shortages

Compounded semaglutide refers to customized versions of the medication prepared by pharmacies, especially during shortages of FDA-approved products like Ozempic and Wegovy. While compounded forms of brand-name medications can make it easier to access the drugs, the quality of such medications often varies.

'Weight cycling'—when someone repeatedly loses and gains weight—can harm an individual's metabolism.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

Celebrities are able to promote prescription drugs on social media without any required mention of potential side effects due to a legal loophole.

How to properly use semaglutides

This podcast with a nutritionist and a medical doctor discusses how useful semaglutide can be for weight loss. It also outlines the need for patients to set reasonable expectations and to make changes to both diet and exercise as part of an overall weight management strategy. The experts note that failure to make meaningful changes outside of using semaglutide may mean patients need to stay on the drug in order to keep the weight off.

GLP-1 helps reduce obesity through a number of mechanisms

Clinical studies show GLP-1 drugs, including semaglutide, promote weight loss through a number of effects. These include reduced appetite, slower emptying of the digestive tract, increased insulin production, and more.

Insurance denials prevent lifesaving care for patients with eating disorders, according to an investigation from The Seattle Times.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

The promises and perils of using at-home genetic tests for your health

A primer on genetic testing, personalized medicine, and the promise of pharmacogenomics–the use of genetics to predict an individual's response to a drug.

Do wearables help those with chronic disease?

The integration of wearable technology in healthcare has promised significant benefits for chronic disease management, yet the actual impact remains underexplored. This systematic review published in the Journal of Medical Internet Research...

Doctors are prescribing social activities—and seeing good results

Physicians, especially in the UK, are asking patients what they enjoy and then prescribing a consistent regimen of doing that type of activity to improve fitness and overall health, including community exercise classes, volunteering, and spending time in nature. This approach may provide better incentives to stick with an activity.

Menopause may become a $600B industry

Companies marketing products and supplements to alleviate menopause symptoms and make life easier during this life stage have become a gold mine. This 2022 article explores how and why companies have swooped into this space, and whether you should trust them or not.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.

A new schizophrenia healthcare model is giving patients more of a role in shaping their own treatments, with good results.

How meal timing factors into health outcomes

The world is trending toward weight gain, a development that comes with a corresponding rise in risk for health conditions, including diabetes and heart disease. This article explores how meal timing has become a factor in nutrition and weight maintenance.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

How semaglutides are both better and worse than we know

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.

Social support plays a critical role in recovery from addiction

This engaging TEDx talk from addiction researcher Jacki Hillios explores addiction recovery through a transformative lens and Phoenix Multisport—an innovative program helping people rebuild their lives through active lifestyles. By living out its core message that people are not defined by their disease, the program demonstrates the power of social support in recovery.